secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001193125-26-095094
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027
--------------------------------------------------------------------------------

- Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.
- Net loss $77.7M for FY2025 vs $58.7M in 2024; net cash used in ops $73.6M (vs $51.3M).
- R&D expenses $69.9M (up from $58.5M) on rezatapopt trial costs; G&A $16.3M (down from $26.9M).
- PYNNACLE Phase 2 enrollment on track; NDA submission for ovarian cancer planned Q1 2027.
- Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C positive ovarian cancer; Phase 1 in NEJM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/0001193125-26-095094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/pmvp-20260306.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-095094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer